{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T03:01:03Z","timestamp":1791687663387,"version":"4.3.4"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jhep.2026.07.016","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T06:47:46Z","timestamp":1784962066000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A framework and shared vocabulary to identify actionable protein biomarkers and enable optimal precision medicine: Myth-busting with unicorn biomarkers"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5026-8740","authenticated-orcid":false,"given":"Morten A.","family":"Karsdal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7952-9297","authenticated-orcid":false,"given":"Anne-Christine","family":"Bay-Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1642-7482","authenticated-orcid":false,"given":"Daniel Guldager","family":"Kring Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9598-4932","authenticated-orcid":false,"given":"Aleksander","family":"Krag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5031-2294","authenticated-orcid":false,"given":"Stine","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9518-0088","authenticated-orcid":false,"given":"Quentin M.","family":"Anstee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana J.","family":"Leeming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1984-1881","authenticated-orcid":false,"given":"Federica","family":"Genovese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilie L.","family":"Bager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Benschop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Ruane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Adya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rn M.","family":"Schattenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6261-1286","authenticated-orcid":false,"given":"Ali","family":"Mobasheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6543-3224","authenticated-orcid":false,"given":"Veronica","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1854-1924","authenticated-orcid":false,"given":"Maja","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6577-5657","authenticated-orcid":false,"given":"Roberto A.","family":"Calle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4427-0128","authenticated-orcid":false,"given":"Patrick","family":"Bossuyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3455-1789","authenticated-orcid":false,"given":"Adam","family":"Platt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0322-0470","authenticated-orcid":false,"given":"Signe H.","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Bonneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6350-5375","authenticated-orcid":false,"given":"Bruno","family":"Golding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Hassanein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanta","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9433-7496","authenticated-orcid":false,"given":"Sarah","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoltan","family":"Derdak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suneil","family":"Hosmane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3059-9133","authenticated-orcid":false,"given":"Paresh","family":"Thakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8173-8258","authenticated-orcid":false,"given":"Virginia B.","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2026.07.016_bib1","article-title":"BEST (Biomarkers, EndpointS, and other tools) resource","author":"Group","year":"2016","journal-title":"Food Drug Adm (US)"},{"key":"10.1016\/j.jhep.2026.07.016_bib2","unstructured":"https:\/\/www.fda.gov\/drugs\/development-resources\/table-surrogate-endpoints-were-basis-drug-approval-or-licensure [n.d]."},{"key":"10.1016\/j.jhep.2026.07.016_bib3","unstructured":"https:\/\/www.ema.europa.eu\/en\/news\/medical-devices-new-guidance-industry-notified-bodies [n.d]."},{"key":"10.1016\/j.jhep.2026.07.016_bib4","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41586-023-06563-x","article-title":"Large-scale plasma proteomics comparisons through genetics and disease associations","volume":"622","author":"Eldjarn","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2026.07.016_bib5","doi-asserted-by":"crossref","unstructured":"Karsdal MA, Delvin E, Christiansen C. Protein fingerprints - relying on and understanding the information of serological protein measurements. ClinBiochem n.d.;44:1278\u20131279.","DOI":"10.1016\/j.clinbiochem.2011.08.1135"},{"key":"10.1016\/j.jhep.2026.07.016_bib6","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abq5095","article-title":"A \u201cbest-in-class\u201d systemic biomarker predictor of clinically relevant knee osteoarthritis structural and pain progression","volume":"9","author":"Zhou","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/j.jhep.2026.07.016_bib7","doi-asserted-by":"crossref","DOI":"10.3109\/1354750X.2013.789084","article-title":"Quantification of \u201cend products\u201d of tissue destruction in inflammation may reflect convergence of cytokine and signaling pathways-implications for modern clinical chemistry","volume":"18","author":"Karsdal","year":"2013","journal-title":"Biomarkers"},{"key":"10.1016\/j.jhep.2026.07.016_bib8","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1172\/JCI63930","article-title":"Adipocyte-derived endotrophin promotes malignant tumor progression","volume":"122","author":"Park","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2026.07.016_bib9","doi-asserted-by":"crossref","DOI":"10.1093\/database\/baab012","article-title":"Post-translational modifications in proteins: resources, tools and prediction methods","volume":"2021","author":"Ramazi","year":"2021","journal-title":"Database"},{"key":"10.1016\/j.jhep.2026.07.016_bib10","unstructured":"https:\/\/clsi.org\/ [n.d]."},{"key":"10.1016\/j.jhep.2026.07.016_bib11","article-title":"BEST (Biomarkers, EndpointS, and other tools) resource","author":"Group","year":"2016","journal-title":"Food Drug Adm (US)"},{"key":"10.1016\/j.jhep.2026.07.016_bib12","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.jhep.2022.11.028","article-title":"NAFLD and NASH biomarker qualification in the LITMUS consortium \u2013 lessons learned","volume":"78","author":"Rasmussen","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.07.016_bib13","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1373\/clinchem.2016.254649","article-title":"Waste, Leaks, and failures in the biomarker pipeline","volume":"63","author":"Ioannidis","year":"2017","journal-title":"Clin Chem"},{"key":"10.1016\/j.jhep.2026.07.016_bib14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/cpt.2554","article-title":"Biomarker qualification at the European medicines agency: a review of biomarker qualification procedures from 2008 to 2020","volume":"112","author":"Bakker","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jhep.2026.07.016_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h5527","article-title":"STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies","author":"Bossuyt","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.jhep.2026.07.016_bib16","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jhep.2014.10.042","article-title":"An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standards","volume":"62","author":"Boursier","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.07.016_bib17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.7326\/M14-0697","article-title":"et alTransparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement","volume":"162","author":"Collins","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2026.07.016_bib18","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70445","article-title":"Surrogate endpoints in regulatory decision-making","volume":"18","author":"Jeng","year":"2025","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jhep.2026.07.016_bib19","unstructured":"Surrogate Endpoint Resources for Drug and Biologic Development | FDA n.d. https:\/\/www.fda.gov\/drugs\/development-resources\/surrogate-endpoint-resources-drug-and-biologic-development (accessed June 14, 2025)."},{"key":"10.1016\/j.jhep.2026.07.016_bib20","series-title":"Reasonably likely surrogate endpoint","author":"Group","year":"2020"},{"key":"10.1016\/j.jhep.2026.07.016_bib21","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/other\/qualification-opinion-gfr-slope-validated-surrogate-endpoint-rct-ckd_en.pdf [n.d]."},{"key":"10.1016\/j.jhep.2026.07.016_bib22","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1002\/cam4.3732","article-title":"Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis","volume":"10","author":"Parker","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.jhep.2026.07.016_bib23","doi-asserted-by":"crossref","DOI":"10.1111\/apt.12820","article-title":"Review article: the efficacy of biomarkers in chronic fibroproliferative diseases - early diagnosis and prognosis, with liver fibrosis as an exemplar","volume":"40","author":"Karsdal","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2026.07.016_bib24","article-title":"Improvement of fibrosis is associated with the decrease of collagen III formation biomarker PRO-C3 in patients with non-alcoholic steatohepatitis","author":"Luo","year":"2017","journal-title":"AASLD LiverLearning\u00ae"},{"key":"10.1016\/j.jhep.2026.07.016_bib25","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1111\/liv.15595","article-title":"Validation of scores of PRO-C3 to predict liver-related events in alcohol-related liver disease","volume":"43","author":"Johansen","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2026.07.016_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-023-04690-7","article-title":"The impact of fibrotic diseases on global mortality from 1990 to 2019","volume":"21","author":"Mutsaers","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.jhep.2026.07.016_bib27","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S2468-1253(24)00274-7","article-title":"Development, validation, and prognostic evaluation of LiverPRO for the prediction of significant liver fibrosis in primary care: a prospective cohort study","volume":"10","author":"Lindvig","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.07.016_bib28","article-title":"Use of bone turnover markers in clinical osteoporosis assessment in women: current issues and future options","volume":"7","author":"Henriksen","year":"2011","journal-title":"Women\u2019s Health"},{"key":"10.1016\/j.jhep.2026.07.016_bib29","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/0006-291X(69)90685-8","article-title":"Studies of an unusual hemoglobin in patients with diabetes mellitus","volume":"36","author":"Rahbar","year":"1969","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jhep.2026.07.016_bib30","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJM197608192950804","article-title":"Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus","volume":"295","author":"Koenig","year":"1976","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2026.07.016_bib31","first-page":"S4","article-title":"Standards of medical care in diabetes--2010","volume":"33","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhep.2026.07.016_bib32","article-title":"Glycated hemoglobin and methods for its point of care testing","volume":"11","author":"Pohanka","year":"2021","journal-title":"Biosensors (Basel)"},{"key":"10.1016\/j.jhep.2026.07.016_bib33","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clinbiochem.2004.09.007","article-title":"Importance of measuring products of non-enzymatic glycation of proteins","volume":"38","author":"Lapolla","year":"2005","journal-title":"Clin Biochem"},{"key":"10.1016\/j.jhep.2026.07.016_bib34","doi-asserted-by":"crossref","first-page":"528","DOI":"10.4103\/2230-8210.98004","article-title":"Drugs affecting HbA1c levels","volume":"16","author":"Unnikrishnan","year":"2012","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.jhep.2026.07.016_bib35","article-title":"Glycated haemoglobin A1c as a risk factor of cardiovascular outcomes and all-cause mortality in diabetic and non-diabetic populations: a systematic review and meta-analysis","volume":"015949","author":"Cavero-Redondo","year":"20177","journal-title":"BMJ Open"},{"key":"10.1016\/j.jhep.2026.07.016_bib36","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0140-6736(09)61969-3","article-title":"Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study","volume":"375","author":"Currie","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2026.07.016_bib37","first-page":"eS7","article-title":"Risks and benefits of attaining HbA(1c) goals: examining the evidence","volume":"110","author":"Shubrook","year":"2010","journal-title":"J Am Osteopath Assoc"},{"key":"10.1016\/j.jhep.2026.07.016_bib38","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1111\/dom.16337","article-title":"Time spent in glycaemic control with sustained body weight reduction with tirzepatide: a post hoc analysis of the SURPASS clinical trial programme","volume":"27","author":"Bergman","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jhep.2026.07.016_bib39","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jhep.2026.07.016_bib40","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1111\/dom.16379","article-title":"et alThe Goldilocks for chronic weight management\u2014Balancing quantity with quality of weight loss","volume":"27","author":"Henriksen","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jhep.2026.07.016_bib41","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jhep.2024.04.034","article-title":"FGF21 agonists: an emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond","volume":"81","author":"Harrison","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.07.016_bib42","series-title":"Anne-Christine Bay-Jensen, Kim Henriksen, et al Biochemistry of collagens, Laminins and Elastin","author":"Karsdal Morten Asser","year":"2019"},{"key":"10.1016\/j.jhep.2026.07.016_bib43","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1093\/clinchem\/44.11.2281","article-title":"Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen","volume":"44","author":"Rosenquist","year":"1998","journal-title":"Clin Chem"},{"key":"10.1016\/j.jhep.2026.07.016_bib44","doi-asserted-by":"crossref","unstructured":"Ravn P, Clemmesen B, Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone n.d.;24:237\u2013244.","DOI":"10.1016\/S8756-3282(98)00183-5"},{"key":"10.1016\/j.jhep.2026.07.016_bib45","doi-asserted-by":"crossref","unstructured":"Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. NEnglJMed n.d.;353:555\u2013565.","DOI":"10.1056\/NEJMoa050336"},{"key":"10.1016\/j.jhep.2026.07.016_bib46","article-title":"Biochemical markers in osteoarthritis with lessons learned from osteoporosis","volume":"37","author":"Karsdal","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jhep.2026.07.016_bib47","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/jbmr.3452","article-title":"Effects of 24 Months of treatment with romosozumab followed by 12 Months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study","volume":"33","author":"McClung","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jhep.2026.07.016_bib48","first-page":"15","article-title":"Serum N-terminal propeptide of collagen type I is associated with the number of bone metastases in breast and prostate cancer and correlates to other bone related markers","volume":"3","author":"Leeming","year":"2011","journal-title":"BiomarkCancer"},{"issue":"Suppl 2","key":"10.1016\/j.jhep.2026.07.016_bib49","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3109\/13697137.2015.1101256","article-title":"Role of biochemical markers in the management of osteoporosis","volume":"18","author":"Henriksen","year":"2015","journal-title":"Climacteric"},{"key":"10.1016\/j.jhep.2026.07.016_bib50","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1210\/er.2010-0006","article-title":"et al Osteoclast activity and subtypes as a function of physiology and pathology--implications for future treatments of osteoporosis","volume":"32","author":"Henriksen","year":"2011","journal-title":"Endocr Rev"},{"key":"10.1016\/j.jhep.2026.07.016_bib51","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00198-025-07422-3","volume":"36","author":"Bhattoa","year":"2025","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jhep.2026.07.016_bib52","doi-asserted-by":"crossref","unstructured":"Henriksen K, Bohren KM, Bay-Jensen AC, Karsdal MA. Should biochemical markers of bone turnover be considered standard practice for safety pharmacology? Biomarkers n.d.;15:195\u2013204.","DOI":"10.3109\/13547500903434519"},{"key":"10.1016\/j.jhep.2026.07.016_bib53","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.joca.2014.07.027","article-title":"Effect of a 16 weeks weight loss program on osteoarthritis biomarkers in obese patients with knee osteoarthritis: a prospective cohort study","volume":"22","author":"Bartels","year":"2014","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.jhep.2026.07.016_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102706","article-title":"Profiling and targeting connective tissue remodeling in autoimmunity - a novel paradigm for diagnosing and treating chronic diseases","volume":"20","author":"Karsdal","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jhep.2026.07.016_bib55","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.addr.2017.07.014","article-title":"The good and the bad collagens of fibrosis \u2013 their role in signaling and organ function","volume":"121","author":"Karsdal","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jhep.2026.07.016_bib56","series-title":"Anne-Christine Bay-Jensen, Kim Henriksen, et al Biochemistry of collagens, Laminins and Elastin","author":"Karsdal Morten Asser","year":"2019"},{"key":"10.1016\/j.jhep.2026.07.016_bib57","first-page":"303","article-title":"The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters","volume":"5","author":"Nielsen","year":"2013","journal-title":"AmJTranslRes"},{"key":"10.1016\/j.jhep.2026.07.016_bib58","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12931-020-01369-1","article-title":"Prolonged Scar-in-a-Jar: an in vitro screening tool for anti-fibrotic therapies using biomarkers of extracellular matrix synthesis","volume":"21","author":"R\u00f8nnow","year":"2020","journal-title":"Respir Res"},{"key":"10.1016\/j.jhep.2026.07.016_bib59","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1080\/14737159.2021.1962711","article-title":"et al.Enzymatic cross-linking of collagens in organ fibrosis - resolution and assessment","volume":"21","author":"Pehrsson","year":"2021","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.jhep.2026.07.016_bib60","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jhep.2020.03.036","article-title":"Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis","volume":"73","author":"Vali","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.07.016_bib61","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S2468-1253(23)00017-1","article-title":"Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study","volume":"8","author":"Vali","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.07.016_bib62","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1136\/gutjnl-2022-327777","article-title":"Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis","volume":"72","author":"Loomba","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2026.07.016_bib63","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S2468-1253(23)00141-3","article-title":"Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis","volume":"8","author":"M\u00f3zes","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.07.016_bib64","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/gutjnl-2021-324243","article-title":"Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis","volume":"71","author":"M\u00f3zes","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2026.07.016_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2026.101746","article-title":"Fibrosis activity versus disease stage: complementary and independent predictors of outcomes in alcohol-related liver disease","author":"Johansen","year":"2026","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2026.07.016_bib66","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S2468-1253(23)00017-1","article-title":"Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study","volume":"8","author":"Vali","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.07.016_bib67","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S2468-1253(23)00141-3","article-title":"Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis","volume":"8","author":"M\u00f3zes","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.07.016_bib68","doi-asserted-by":"crossref","DOI":"10.1002\/hep.30163","article-title":"ADAPT: an algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis","volume":"69","author":"Daniels","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.07.016_bib69","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1111\/liv.15595","article-title":"Validation of scores of PRO-C3 to predict liver-related events in alcohol-related liver disease","volume":"43","author":"Johansen","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2026.07.016_bib70","doi-asserted-by":"crossref","DOI":"10.2337\/dc18-2578","article-title":"Use of plasma fragments of propeptides of Type III, V, and VI procollagen for the detection of liver fibrosis in type 2 diabetes","volume":"42","author":"Bril","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhep.2026.07.016_bib71","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2026.07.016_bib72","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/apt.70376","article-title":"Exploration of multiple non-invasive tests for assessing response to treatment in a semaglutide phase 2b trial in patients with MASH","volume":"63","author":"Nitze","year":"2026","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2026.07.016_bib73","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/hep4.1657","article-title":"Effects of resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH","volume":"5","author":"Harrison","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2026.07.016_bib74","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2026.07.016_bib75","unstructured":"https:\/\/www.roche.com\/media\/releases\/med-cor-2025-05-06 [n.d]."},{"key":"10.1016\/j.jhep.2026.07.016_bib76","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cgh.2014.04.039","article-title":"FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice","volume":"13","author":"Tapper","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.07.016_bib77","unstructured":"https:\/\/www.accessdata.fda.gov\/cdrh_docs\/reviews\/DEN190056.pdf [n.d]."},{"key":"10.1016\/j.jhep.2026.07.016_bib78","unstructured":"https:\/\/www.fda.gov\/drugs\/drug-alerts-and-statements\/fda-accepts-proposal-reasonably-likely-surrogate-endpoint-mash-all-cause-mortality-or-liver-related [n.d]."},{"key":"10.1016\/j.jhep.2026.07.016_bib79","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3109\/13547500903434519","article-title":"Should biochemical markers of bone turnover be considered standard practice for safety pharmacology?","volume":"15","author":"Henriksen","year":"2010","journal-title":"Biomarkers"},{"key":"10.1016\/j.jhep.2026.07.016_bib80","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1373\/clinchem.2016.254649","article-title":"Waste, leaks, and failures in the biomarker pipeline","volume":"63","author":"Ioannidis","year":"2017","journal-title":"Clin Chem"},{"key":"10.1016\/j.jhep.2026.07.016_bib81","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1002\/cam4.3732","article-title":"Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis","volume":"10","author":"Parker","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.jhep.2026.07.016_bib82","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/cpt.3531","article-title":"Urinary kidney injury biomarker profiles in healthy individuals and after nephrotoxic and ischemic injury","volume":"117","author":"Waikar","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jhep.2026.07.016_bib83","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S2213-8587(24)00092-5","article-title":"Bone mineral density as a surrogate endpoint for fracture risk reduction in clinical trials of osteoporosis therapies: an update on SABRE","volume":"12","author":"Black","year":"2024","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826027443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826027443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:26:35Z","timestamp":1788470795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827826027443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":83,"alternative-id":["S0168827826027443"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2026.07.016","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A framework and shared vocabulary to identify actionable protein biomarkers and enable optimal precision medicine: Myth-busting with unicorn biomarkers","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2026.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}